Technical Analysis for RPRX - Royalty Pharma plc

Grade Last Price % Change Price Change
C 51.34 1.82% 0.92
RPRX closed up 0.14 percent on Thursday, January 21, 2021, on 1.15 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical RPRX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 1.82%
NR7-2 Range Contraction 1.82%
Inside Day Range Contraction 1.82%
MACD Bearish Signal Line Cross Bearish 1.97%
Slingshot Bullish Bullish Swing Setup 1.97%
NR7 Range Contraction 1.97%
NR7-2 Range Contraction 1.97%
NR7 Range Contraction -0.98%
NR7-2 Range Contraction -0.98%
Stochastic Reached Overbought Strength -0.98%
Older End-of-Day Signals for RPRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 2 hours ago
Rose Above Previous Day's High about 5 hours ago
Outside Day about 5 hours ago
20 DMA Support about 5 hours ago
60 Minute Opening Range Breakout about 5 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Industry Pharmaceutical Products Drug Development HIV Biopharmaceutical Products Biopharmaceutical Industry Drug Development Services

Is RPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 56.5
52 Week Low 34.8
Average Volume 2,848,765
200-Day Moving Average 0.00
50-Day Moving Average 45.30
20-Day Moving Average 49.74
10-Day Moving Average 50.72
Average True Range 2.01
ADX 33.98
+DI 25.55
-DI 15.85
Chandelier Exit (Long, 3 ATRs ) 47.19
Chandelier Exit (Short, 3 ATRs ) 49.43
Upper Bollinger Band 52.47
Lower Bollinger Band 47.02
Percent B (%b) 0.62
BandWidth 10.95
MACD Line 1.67
MACD Signal Line 1.80
MACD Histogram -0.1293
Fundamentals Value
Market Cap 18.45 Billion
Num Shares 366 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -81.19
Price-to-Sales 12.88
Price-to-Book 5.94
PEG Ratio -0.02
Dividend 0.60
Dividend Yield 1.19%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.16
Resistance 3 (R3) 52.29 51.84 51.87
Resistance 2 (R2) 51.84 51.40 51.78 51.77
Resistance 1 (R1) 51.13 51.12 51.49 51.00 51.68
Pivot Point 50.68 50.68 50.86 50.62 50.68
Support 1 (S1) 49.97 50.24 50.33 49.84 49.16
Support 2 (S2) 49.52 49.96 49.46 49.07
Support 3 (S3) 48.81 49.52 48.97
Support 4 (S4) 48.68